Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NAMS

NewAmsterdam Pharma Company N.V.

Healthcare | Biotechnology

No licensed closing price on file for NAMS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.15

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:14 UTC.

What NewAmsterdam Pharma Company N.V. does

The company is a biopharmaceutical firm developing obicetrapib, an oral cholesteryl ester transfer protein inhibitor designed to lower LDL cholesterol in patients with cardiovascular disease whose existing treatments are inadequate or poorly tolerated. The company has completed Phase 3 trials showing obicetrapib met primary endpoints with significant LDL-C reductions when used alone or combined with ezetimibe as an add-on to statin therapy, and the drug has been tested in over 3,500 patients with a tolerability profile similar to placebo.

Summarized from NewAmsterdam Pharma Company N.V.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.15

Revenue, margins & earnings

FY2022: net loss $23M on revenue $103M$103MFY2022FY2023: net loss $177M on revenue $14M$14MFY2023FY2024: net loss $242M on revenue $46M$46MFY2024FY2025: net loss $204M on revenue $23M$23MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02Chief Scientific OfficerOption (right to buy)Option exercise-50,246—
  • 2026-10-02Chief Scientific OfficerOption exercise50,246—
  • 2026-10-02Chief Scientific OfficerSale-50,246$1.26M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does NewAmsterdam Pharma Company N.V. do?

The company is a biopharmaceutical firm developing obicetrapib, an oral cholesteryl ester transfer protein inhibitor designed to lower LDL cholesterol in patients with cardiovascular disease whose existing treatments are inadequate or poorly tolerated.

When did NAMS last file with the SEC?

NewAmsterdam Pharma Company N.V.'s most recent SEC filing on record is a 8-K filed 2026-06-03. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:14 UTC. This page is also available as JSON at /api/data?ticker=NAMS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NAMS and 5,000+ tickers.

Create a free account — keep NAMS
For your agent
GET /api/data?ticker=NAMS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt